{"id":8334,"date":"2023-08-10T14:29:40","date_gmt":"2023-08-10T14:29:40","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=8334"},"modified":"2023-08-10T14:29:40","modified_gmt":"2023-08-10T14:29:40","slug":"pd-1-expanding-beyond-cancer-research","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/pd-1-expanding-beyond-cancer-research\/","title":{"rendered":"PD-1: Expanding Beyond Cancer Research"},"content":{"rendered":"\n

Introduction to PD-1<\/h2>\n\n\n\n

There has been significant interest in the role of programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) in modulating immune responses. The emergence of PD-1-targeted therapies has revolutionised cancer treatment, leading to a better understanding of immune checkpoint mechanisms and their uses in various research fields.<\/p>\n\n\n\n

This paper offers a review of significant publications on the use of PD-1 antibodies in cancer, immunology, and Alzheimer\u2019s disease research. ProSci highlights the importance of PD-1 antibodies in resolving the complicated interactions between the immune system and pathological conditions as well as their potential to create novel therapeutic approaches.<\/p>\n\n\n\n

Download the white paper\u00a0here<\/a>.<\/p>\n\n\n\n

\"Anti<\/figure>\n\n\n\n

Enhancing Immunology Research & Therapy Development<\/h2>\n\n\n\n

The ProSci PD-1 antibody has been used in a variety of cancer, immunology, and Alzheimer\u2019s disease investigations. Researchers have successfully detected PD-1 expression in several study settings with the highly specific rabbit polyclonal anti-PD-1 antibody (ProSci Cat #: 4065<\/a>).<\/p>\n\n\n\n

The ProSci PD-1 antibody has been found to be effective in improving understanding of the immune system\u2019s participation in many pathological conditions, and it has aided in the development of novel therapeutic strategies.<\/p>\n\n\n\n

Learn More:\u00a0Caltag Medsystems – ProSci – Product No.4065<\/a><\/p>\n\n\n\n

\"ProSci<\/figure>\n\n\n\n

Figure 1: ProSci PD-1 Antibody (ProSci Cat #: 4065<\/a>) Western Blot Validation in Human and Mouse Cell Lines<\/p>\n\n\n\n

Loading: 15\u03bcg of lysates per lane. Antibodies: PD-1 (ProSci Cat #: 4065<\/a>) (4\u03bcg\/mL), 1h incubation at RT in 5% NFDM\/TBST<\/p>\n\n\n\n

Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution<\/p>\n\n\n\n

\"ProSci<\/figure>\n\n\n\n

Figure 2: ProSci PD-1 Antibody (ProSci Cat #: 4065<\/a>) Immunohistochemistry Validation of PD-1in Human Tonsil Tissue Tissue was fixed with formaldehyde and blocked with 10% serum for 1h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4\u00b0C. A goat anti-rabbit IgG H&amp;L (HRP) at 1:250 was used as a secondary antibody and was counter-stained with Hematoxylin.<\/p>\n\n\n\n

\n\n\n\n

Utilisation of ProSci PD-1 Antibody in Immunology Research:<\/h2>\n\n\n\n

The ProSci PD-1 antibody facilitated key insights into how BCG vaccination and GSH enhancement modulate PD-1 expression, bolstering its versatility.<\/h3>\n\n\n\n

In the study \u201cElucidating the Efficacy of the Bacille Calmette-Guerin Vaccination in Conjunction with First Line Antibiotics and Liposomal Glutathione\u201d 1, researchers investigated the combined effects of BCG (Bacille Calmette-Guerin) vaccination and ex-vivo glutathione (GSH) enhancement on improving immune responses against Mycobacterium tuberculosis (M. tb) infection.<\/p>\n\n\n\n

They examined immune response effectiveness, CD4+ and CD8+ T cells in granulomas, liposomal glutathione (L-GSH) response, antibiotic levels, PD-1 expression, and autophagy induction. The results demonstrated that BCG vaccination, along with GSH enhancement, prevented CD4+ and CD8+ T cell loss in granulomas, improved M. tb infection control, reduced PD-1 expression, and increased autophagy and cytokine production (IFN-\u03b3 and TNF-\u03b1).<\/p>\n\n\n\n

The ProSci rabbit polyclonal anti-PD-1 antibody (ProSci Cat #: 4065<\/a>) was used to measure PD-1 expression in FFPE tissue samples. The results revealed a decrease in PD-1 expression due to BCG vaccination in immune responses against M. tb infection.<\/p>\n\n\n\n

\n\n\n\n

Utilisation of ProSci PD-1 and PD-L1 Antibodies in Alzheimer\u2019s Disease Research:<\/h2>\n\n\n\n

ProSci PD-1 and PD-L1 antibodies uniquely illuminated the PD-1\/PD-L1 axis\u2019 role in Alzheimer\u2019s pathology and neuroinflammation.<\/h3>\n\n\n\n

In the study \u201cMicroglial PD-1 stimulation by astrocytic PD-L1 suppresses neuroinflammation and Alzheimer\u2019s disease pathology\u201d 2, researchers investigated the role of the PD-1\/PD-L1 immune checkpoint in Alzheimer\u2019s disease (AD). They demonstrated upregulated expression of PD-L1 in astrocytes and PD-1 in microglia surrounding amyloid plaques in AD patients and the APP\/PS1 mouse model.<\/p>\n\n\n\n

Deletion of microglial PD-1 resulted in increased amyloid-beta (A\u03b2) deposition, reduced microglial A\u03b2 uptake, and decreased expression of the A\u03b2 receptor CD36 on microglia. These findings suggest that ineffective immune regulation by the PD-1\/PD-L1 axis contributes to A\u03b2 plaque deposition during chronic neuroinflammation in AD.<\/p>\n\n\n\n

The ProSci rabbit polyclonal anti-PD-1 (ProSci Cat #: 4065<\/a>) and anti-PD-L1 (ProSci Cat #: 4059<\/a>) antibodies were used to measure the expression levels of PD-1 and PD-L1 in FFPE tissue samples from Alzheimer\u2019s patients.<\/p>\n\n\n\n

\n\n\n\n

Utilisation of ProSci PD-1 Antibody in Cancer Research:<\/h2>\n\n\n\n

ProSci\u2019s PD-1 antibody facilitated a detailed analysis of rare D-LPHL, underscoring diagnostic versatility.<\/h3>\n\n\n\n

In the study \u201cDiffuse variant of lymphocyte-predominant Hodgkin lymphoma: a diagnostic challenge\u201d 3, researchers presented a rare case of diffuse variant nodular lymphocyte-predominant Hodgkin lymphoma (D-LPHL) in a 35-year-old Caucasian female with left cervical and right axillary lymphadenopathy. Histopathological examination revealed large atypical lymphoid cells with a characteristic phenotype. Immunohistochemical studies confirmed the diffuse nature of the lymphoid proliferation, and the associated T cell microenvironment showed increased CD57(+) T cells. The report discusses the diagnostic criteria and provides a review of the literature on the differential diagnosis of this rare condition.<\/p>\n\n\n\n

The ProSci rabbit polyclonal anti-PD-1 (ProSci Cat #: 4065<\/a>) antibody was used to detect the expression of PD-1 in FFPE tissue sample from this rare case of diffuse variant nodular lymphocyte-predominant Hodgkin lymphoma. The study highlighted the presence of PD-1-positive T cells exhibiting rosette formation around LP-type HL cells.<\/p>\n\n\n\n

Research Tools<\/h2>\n\n\n\n

This paper highlights the significance of the ProSci PD-1 antibody in cancer, immunology, and Alzheimer\u2019s disease research, demonstrating its effectiveness in understanding the immune system\u2019s
role in various pathological conditions. The paper showcases the antibody\u2019s potential in developing
novel therapeutic approaches and resolving complex interactions between the immune system and
diseases by analyzing key publications.<\/p>\n\n\n\n

For more information on PD-1 research tools and other high-performance antibody tools, contact us<\/a>.<\/p>\n\n\n\n

Originally posted on www.prosci-inc.com\/blog\/pd-1-beyond-cancer-research\/?utm_source=ActiveCampaign&utm_medium=email&utm_content=PD-1%3A+Expanding+Beyond+Cancer+Research+%7C+ProSci%2C+A+Genesee+Scientific+Company&utm_campaign=PD-1+Paper<\/a><\/p>\n\n\n\n

Caltag Medsystems<\/a> is the distributor of ProSci <\/a>products in the UK and Ireland. If you have any questions about these products, please contact us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

ProSci details the importance of PD-1 antibodies are important in resolving complex interactions between the immune system & pathological conditions.<\/p>\n","protected":false},"author":13,"featured_media":8339,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[132,10,1,29],"tags":[185,7,50,157,77],"class_list":["post-8334","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-antibodies","category-cancer","category-general-information","category-immunology","tag-antibodies","tag-cancer","tag-immunology","tag-pd-1","tag-prosci"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=8334"}],"version-history":[{"count":5,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8334\/revisions"}],"predecessor-version":[{"id":8340,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8334\/revisions\/8340"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/8339"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=8334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=8334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=8334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}